IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 247 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $122 | -84.7% | 26,791 | -76.4% | 0.01% | -88.1% |
| Q2 2023 | $798 | +127.4% | 113,329 | +97.3% | 0.10% | +215.6% |
| Q1 2023 | $351 | -99.9% | 57,448 | +30.8% | 0.03% | -23.8% |
| Q3 2022 | $421,000 | +184.5% | 43,907 | +226.6% | 0.04% | +147.1% |
| Q2 2022 | $148,000 | -62.6% | 13,443 | -35.2% | 0.02% | -61.4% |
| Q4 2021 | $396,000 | +89.5% | 20,744 | +144.3% | 0.04% | +76.0% |
| Q3 2021 | $209,000 | -59.7% | 8,490 | -48.2% | 0.02% | -57.6% |
| Q1 2021 | $519,000 | +45.0% | 16,388 | +25.6% | 0.06% | +9.3% |
| Q2 2020 | $358,000 | +53.6% | 13,051 | +55.2% | 0.05% | +45.9% |
| Q4 2019 | $233,000 | -15.9% | 8,409 | -71.1% | 0.04% | -17.8% |
| Q1 2019 | $277,000 | -1.8% | 29,085 | +16.2% | 0.04% | +15.4% |
| Q3 2018 | $282,000 | +112.0% | 25,033 | +46.0% | 0.04% | +77.3% |
| Q3 2017 | $133,000 | – | 17,143 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 12,201,261 | $203,150,000 | 4.07% |
| Paradigm Biocapital Advisors LP | 907,428 | $15,109,000 | 4.00% |
| Avoro Capital Advisors LLC | 9,125,000 | $151,931,000 | 2.77% |
| Logos Global Management LP | 1,000,000 | $16,650,000 | 2.16% |
| Avidity Partners Management LP | 6,043,219 | $100,620,000 | 2.10% |
| Orbimed Advisors | 6,633,006 | $110,440,000 | 1.79% |
| Parametrica Management Ltd | 134,679 | $2,240,000 | 1.66% |
| Boxer Capital, LLC | 1,935,133 | $32,220,000 | 1.66% |
| Fairmount Funds Management LLC | 389,588 | $6,487,000 | 1.53% |
| Long Focus Capital Management, LLC | 705,000 | $11,738,000 | 1.51% |